Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no...
-
Upload
sherman-austin -
Category
Documents
-
view
217 -
download
1
Transcript of Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no...
![Page 1: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/1.jpg)
Japan Urology Association
Disclosure of COI
Presenter Shinji Kageyama, MD I declare that there are no conflicts of interest associated
with this study.
![Page 2: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/2.jpg)
Acitive Surveillance
AS: chose progress observation approach rather than actual carcinostatic treatment
Feel uneasiness by patientsReceived many inquiries by
patients seeking for something better once PSA level increases
![Page 3: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/3.jpg)
3
Case 61-year-old patient (presently 71 years old)
Patient’s Option: Observation of PSA levelHistory of disease:In 2004 Biopsy at one hospital in Hamamatsu City and detected PSA 5.2 and found that G3+4 was 2/6. Diagnosis – T2aNoMo. Selected “progress observation” per his request.
In 2006 re-biopsy at the same hospitalDecided for continuation of “progress observation” for G3+4 was 1/6.PSA increased to 7.2 at most; PSA stayed between 5 and 6
In April, 2013, a patient moved to Shizuoka CityContinued “progress observation” at my clinicPresent symptoms/test results: TG, LDL-C is a little higher than limits; otherwise, no mentionable symptoms
![Page 4: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/4.jpg)
G3+4 G3+4 Began observation at my clinic
Feb-
06
May-0
6
Aug-0
6
Nov-0
6
Feb-
07
May-0
7
Aug-0
7
Nov-0
7
Feb-
08
May-0
8
Aug-0
8
Nov-0
8
Feb-
09
May-0
9
Aug-0
9
Nov-0
9
Feb-
10
May-1
0
Aug-1
0
Nov-1
0
Feb-
11
May-1
1
Aug-1
1
Nov-1
1
Feb-
12
May-1
2
Aug-1
2
Nov-1
20
1
2
3
4
5
6
7
8
9
10PSA
PSA
2/6 1/6MRI
![Page 5: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/5.jpg)
Treatment for Minimally Invasive Cancer
Metformin Vit D Curcumin Agaricus PDT Peptide Vaccine
![Page 6: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/6.jpg)
6
![Page 7: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/7.jpg)
7
Gold LotionTM
Extract of Citrus produced in Japan
Unsyu Mikan (tangerin), Citrus limon, navel oranges, Citrus Hassaku, Citrus natsudaidai, Miyauchi Iyo hort, Aloe
7
![Page 8: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/8.jpg)
8
Compounds contained in Citrus Peel Extract
• Pectin• anti-ulcer 、 disinfection 、
immune activation• Essential oil
• Terpenoids: limonene, linalool, etc.
• other volatile oil• antioxydation 、 disinfec
tion • Flavonoids
• Polyhydroxyflav(an)ones (PHFs)
• PMFs – polymethoxyflavones• anti-
immflamation 、 anti-carcinogenesis 、 antioxydation 、 anti-atherosclerosis effects
• Carotenoids• Hesperidin• Narindin
• Anti-cancer
![Page 9: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/9.jpg)
GL の各種パラメータに対する影響
Anti-immflammation
Inhibit metastasis
Induction ofApoptosis
Inhibit proliferation
![Page 10: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/10.jpg)
10
Inhibition of LNCaP, PC-3 cell Proliferation by Hesperidin
Effective on both androgen dependent/non-dependent
![Page 11: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/11.jpg)
PC-3 derived xenograft model11
Professor Min-Hsiung Pan, Taiwan University, TaiwanProfessor Chi-Tang Ho, Rutgers University, USA
Food & Function, 2013, DOI: 10.1039/c3fo60037h
![Page 12: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/12.jpg)
Results
Inhibit tumor proliferation (peritoneal application)
Inhibit tumor proliferation(oral application)
Oral application proved to be effective against androgen non-dependent cancer
![Page 13: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/13.jpg)
Case 61-year-old patient (presently 71 years old)
Began GL oral application
Began observation at my clinic
Mar-1
3
Apr-1
3
May-1
3
Jun-
13
Jul-1
3
Aug-1
3
Sep-
13
Oct-1
3
Nov-1
3
Dec-1
3
Jan-
14
Feb-
14
Mar-1
4
Apr-1
4
May-1
4
Jun-
14
Jul-1
4
Aug-1
40
2
4
6
8
10
12
PSA
PSA
![Page 14: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/14.jpg)
前立腺がんに対する GL 使用GL Oral Application against Prostate Cancer
14
Yearstarted
Age Years of applica-tion
Dosage( CC)
PSAStartingPSA
Least PSA level
Other combined treatment
2004 80 1yr. 10 278 1 LH-RH
2005 67 2yr. 15 24.4 13.3 LH-RH( after
application13.3⇒0.03 )
2008 66 6yr. 10 0.3 0.03 after brachy therapy
2012 70 2yr. 10 ~30
0.2 0.05 daVinc
2013 69 1.5yr. 30 16.1 10.5 with other supplement
2014 71 4mos.
15 10.1 6.9 none
Data provided by Miyauchi Citrus Research Center, Ltd.
![Page 15: Japan Urology Association Disclosure of COI PresenterShinji Kageyama, MD I declare that there are no conflicts of interest associated with this study.](https://reader035.fdocuments.in/reader035/viewer/2022062721/56649f255503460f94c3c6f7/html5/thumbnails/15.jpg)
Issues to be considered Considering this case, was Increased PSA at
the beginning of this observation at my clinic a palindromia of cancer?
Considering decreased PSA by GL application, simply treated inflammation? Recommended strongly another biopsy
Unclear most adequate dosage of GL What about testosterone level? Require longer observation
15